AKRO

Akero Therapeutics, Inc.

Latest Form 4:Sale$552KbyRolph Timothy (Chief Scientific Officer) · filed Sep 10, 2025

Akero Therapeutics, Inc. (AKRO) has 15 SEC Form 4 filings (33 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Dec 9, 2025.

Insiders have net sold $552K over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Andrew Cheng
  • Employees:69
  • HQ:South San Francisco, CA, US
  • IPO:2019-06-20

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$552K

reported sales (SEC code S)

Unique Insiders

1

in the rolling window

Source
Rolph TimothyFirst filing
Sale$552KSep 10SEC ↗